Loading...

People

Loading...

Nicola P. Klein, MD, PhD

Nicola P. Klein, MD, PhDKaiser Permanente Vaccine Study Center
1 Kaiser Plaza, 16th Floor
Oakland, CA 94612

(510) 267-7540 (phone)
nicola.klein@kp.org

Nicola P. Klein, MD, PhD, is a research scientist at the Kaiser Permanente Northern California Division of Research; co-director of the Kaiser Permanente Vaccine Study Center; and clinical instructor in the Department of Pediatrics, Lucile Salter Packard Children’s Hospital at Stanford, Stanford University School of Medicine. Dr. Klein’s research interests include vaccine safety and efficacy, genetic influences on vaccine responses, and vaccine responses among at-risk populations (premature infants and children with chronic or genetic diseases). Dr. Klein received her medical and doctorate degrees at New York University School of Medicine.

Current Position(s):

  • Research Scientist II, Division of Research, Kaiser Permanente Northern California
  • Co-Director, Kaiser Permanente Vaccine Study Center, Kaiser Permanente Northern California
  • Adjunct Clinical Instructor, Department of Pediatrics, Lucile Salter Packard Children’s Hospital at Stanford, Stanford University School of Medicine

Primary Research Interests:

  • Vaccine safety and efficacy
  • Genetic influences on vaccine responses
  • Vaccine responses among at risk populations (premature infants, children with chronic or genetic diseases).

Related Web sites

Loading...

A Phase IIIb, Open-Label, Controlled, Multi-Center Study to Evaluate the Persistence of Antibody Responses Among Children who Previously Received Novartis MenACWY Conjugate Vaccine (Novartis Protocol V59P14E1)

Funder: Novartis
Principal Investigator: Klein, Nicola

Loading...

A Phase 3b, Open-Label, Randomized, Parallel-Group, Multicenter Study to Evaluate the Safety of Novartis Men ACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants

Funder: Novartis
Principal Investigator: Klein, Nicola

Loading...

Phase III, Partially Double-Blind Study to Evaluate Consistency and Immunogenicity of 3 Lots of GSK Biologicals’ Hib Conjugate Vaccine 208108 Versus ActHIB and Pentacel at 2, 4, 6 and 15-18 Months of Age in Healthy Infants

Funder: GlaxoSmithKline
Principal Investigator: Klein, Nicola

Loading...

Immunogenicity and Safety of a New Meningococcal Conjugate Vaccine Administered to Two to 10 year olds

Funder: Novartis
Principal Investigator: Klein, Nicola

Loading...

Post-Licensure Safety Surveillance Study of Routine Use of Pentacel

Funder: Sanofi Pasteur
Principal Investigator: Klein, Nicola

Loading...

Post-licensure Safety Surveillance Study of Routine Use of Meningococcal (Groups A, C, Y, and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra) in Recipients Two to 10 Years of Age

Funder: Sanofi Pasteur
Principal Investigator: Klein, Nicola

Loading...

A Post-licensure Surveillance Program for the Safety of GARDASIL in a Managed Care Organization Setting

Funder: Merck and Co., Inc.
Principal Investigator: Klein, Nicola

Loading...

Vaccine Safety Databank Evaluation of Human Papilloma Virus Associated Outcomes

Funder: Centers for Disease Control and Prevention
Principal Investigator: Klein, Nicola

Loading...

Vaccine Safety Datalink

Funder: Centers for Disease Control and Prevention
Principal Investigator: Klein, Nicola

Loading...

Clinical Immunization Safety Assessment Network

Funder: Centers for Disease Control and Prevention
Principal Investigator: Klein, Nicola